Regulators have published results from a six-year international active pharmaceutical ingredient inspection programme that Johnson Matthey says benefits companies and authorities.
We have arrived in Philadelphia to report on the major trends at CPhI North America including continuous manufacturing, cell and gene therapies, and the changing nature of contract service relationships.
There is no slowdown in sight, says Avid Bioservices CEO, as the company today announces further expansion to support new client projects and optimize its novel CHO-based expression system.
Dr. Bertalan Mesko discusses the role of artificial intelligence in the future of health care, how patients are driving adoption – and the seemingly thin line between “healing” and “upgrading.”
Mayne Pharma has opened a new 126,000-square-foot oral solid-dose manufacturing facility to meet demand driven by new product launches – and new revenue stream from its CDMO business.
The fourth industrial revolution is here, and some countries are embracing digitisation and advanced manufacturing techniques faster than others, says Siemens exec.
Pills embedded with sensor technology that verifies a patient has taken their medication can improve adherence and provide data on adverse effects, says Proteus Digital Health’s Nik Leist.
INTERPHEX 2018 has kicked off in New York City, and we are here reporting on all things drug formulation, ingredient manufacturing, and contract partnerships for commercial production.
Almac Group has expanded its commercial packaging capabilities to meet a “significant increase” in demand for complex kit assembly as biopharma brings more advanced sterile and biological products to the market, says CDMO.
The US FDA has issued a recall of non-expired products marketed as sterile made by Coastal Meds after an investigation of the outsourcing facility found poor sterile production practices.
China is becoming a fundamental player and is expected to reach market parity with the combined top five European countries by 2022, though the US still dominates, says industry expert.
Pharma must brace itself for production scheduling clashes and cost challenges ahead of next year’s Falsified Medicines Directive (FMD) says PharmSource.
